Voozh

From Wikipedia, the free encyclopedia

Otenzepad
Clinical data
👁 Image Structure of Otenzepad
Routes of administration	oral
Pharmacokinetic data
Bioavailability	45% (oral)^[1]
Elimination half-life	2.5h
Identifiers
IUPAC name 11-[2-[2-(diethylaminomethyl)piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
CAS Number	102394-31-0^{👁 check Y}
PubChem CID	107867
IUPHAR/BPS	309
ChemSpider	97004
UNII	OM7J0XAL0S
ChEBI	CHEBI:111174
ChEMBL	ChEMBL17045
CompTox Dashboard (EPA)	DTXSID0045674 👁 Edit this at Wikidata
ECHA InfoCard	100.220.541 👁 Edit this at Wikidata
Chemical and physical data
Formula	C₂₄H₃₁N₅O₂
Molar mass	421.545 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCN(CC)CC1CCCCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
InChI InChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31) Key:UBRKDAVQCKZSPO-UHFFFAOYSA-N

Otenzepad is a competitive muscarinic receptor antagonist that is relatively selective at the M2 receptor. It was investigated as a treatment for arrhythmia and bradycardia due to its cardioselectivity but research ceased after stage III clinical trials. The drug was originally developed by the German pharmaceutical company, Boehringer Ingelheim Pharma KG.^[1]

Pharmacodynamics

The (+)-enantiomer has 8 times greater potency at the M2 receptor than the (-)-enantiomer.^[1]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Otenzepad". National Centre for Advancing Translational Sciences. Retrieved 10 June 2021.
^ ^a ^b ^c ^d ^e Buckley NJ, Bonner TI, Buckley CM, Brann MR (1989). "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells". Mol. Pharmacol. 35 (4): 469–76. doi:10.1016/S0026-895X(25)11261-3. PMID 2704370.